GlassScriptPhysician profile
Omer Ahmed
NPI 1962429431
$2,218.58
in general payments reported to CMS, 2019-2025
26 companies · $37.48 in 2025
The $37.48 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $417 · 2021: $412 · 2022: $401 · 2023: $427 · 2024: $85.52 · 2025: $37.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $350.95 | 2021-2025 | Verquvo, Belsomra, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.39 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $197.32 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $172.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $130.34 | 2019-2022 | |
| Pfizer INC. | $112.46 | 2019-2024 | |
| Amgen INC. | $110.23 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.10 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $104.87 | 2019-2024 | |
| Abbvie INC. | $87.84 | 2020-2023 | Ubrelvy |
| Smith+Nephew, INC. | $81.37 | 2019-2021 | |
| Lilly USA, LLC | $79.45 | 2020-2023 | Jardiance, Mounjaro |
| Novo Nordisk INC | $72.51 | 2019-2020 | |
| Astellas Pharma US INC | $70.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.78 | 2019-2023 | Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $46.72 | 2021-2022 | |
| Esperion Therapeutics, INC. | $40.87 | 2020-2021 | |
| Eisai INC. | $40.83 | 2020 | |
| Organogenesis INC. | $24.61 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.99 | 2022 | |
| Dexcom, INC. | $21.25 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $20.96 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.87 | 2021 | |
| Allergan, INC. | $18.72 | 2019 | |
| Osiris Therapeutics INC. | $18.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.